TRPM8 and peripheral neuropathy: In an in vivo model of oxaliplatin peripheral neuropathy, compound 40 (1μg, s.c.)significantly reduced cold-induced paw licking 15 min after administration, with maximum and sustained activity from 30 to 60 min, an antiallodynic activity that was higher or equivalent to other described TRPM8 antagonists.